343.1K XNAS Volume
XNAS 14 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mehrotra Ravi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Ann Nelson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Kaan Certel | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 340,000 | 340,000 | - | - | Stock Option (Right to Buy) | |
| Robert L. Rosiello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Rainer J. Boehm | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Elliott M. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Michelle C. Werner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kaan Certel | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Thomas McCauley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Thomas McCauley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Reed Joshua | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Schade Stanton Christian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 512,848 | 512,848 | - | - | Stock Option (Right to Buy) | |
| Karande Mahesh | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 314,326 | 314,326 | - | - | Stock Option (Right to Buy) | |
| Zeng Ling | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 209,551 | 209,551 | - | - | Stock Option (Right to Buy) | |
| Yan Moore | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Michelle C. Werner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 36,713 | 36,713 | - | - | Stock Option (Right to Buy) | |
| Schade Christian Stanton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 36,713 | 36,713 | - | - | Stock Option (Right to Buy) | |
| Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 36,713 | 36,713 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Noubar B. Afeyan | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Rainer J. Boehm | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Elliott M. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 02 Jun 2023 | 5,000 | 739,118 | - | 8 | 40,000 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 01 May 2023 | 5,000 | 744,118 | - | 8 | 40,000 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 06 Apr 2023 | 5,000 | 749,118 | - | 8 | 40,000 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 17 Mar 2023 | 10,000 | 754,118 | - | 8 | 80,000 | Common Stock |
| Yan Moore | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 55,000 | 55,000 | - | - | Option (Right to Buy) | |
| Ling Zeng | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 55,000 | 55,000 | - | - | Option (Right to Buy) | |
| Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 170,000 | 170,000 | - | - | Option (Right to Buy) | |
| Kevin McManus | Chief Human Resources Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 55,000 | 55,000 | - | - | Option (Right to Buy) | |
| Thomas McCauley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 55,000 | 55,000 | - | - | Option (Right to Buy) | |
| Joshua Reed | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 55,000 | 55,000 | - | - | Option (Right to Buy) | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 10 Jan 2023 | 20,000 | 764,118 | - | 8 | 160,000 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 14 Sep 2022 | 10,000 | 784,118 | - | 8 | 80,000 | Common Stock |
| Rainer Boehm | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 36,713 | 36,713 | - | - | Option (Right to Buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Elliott M. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Noubar B. Afeyan | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Joshua Reed | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 320,000 | 320,000 | - | - | Option (Right to Buy) | |
| Kevin McManus | Chief Human Resources Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 125,000 | 125,000 | - | - | Option (Right to Buy) | |
| Ling Zeng | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 270,000 | 270,000 | - | - | Option (Right to Buy) | |
| Thomas McCauley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 110,000 | 110,000 | - | - | Option (Right to Buy) | |
| Mahesh Karande | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 340,000 | 340,000 | - | - | Option (Right to Buy) | |
| Roger Sawhney | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 60,000 | 60,000 | - | - | Option (Right to Buy) | |
| Mahesh Karande | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.53 per share. | 01 Feb 2022 | 11,300 | 117,711 | - | 0.5 | 5,989 | Common Stock |
| Mahesh Karande | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 11,300 | 884,071 | - | - | Option (Right to Buy) | |
| Yan Moore | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 477,715 | 477,715 | - | - | Option (Right to Buy) | |
| Roger Sawhney | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 03 Aug 2021 | 2,941 | 2,941 | - | 17 | 49,997 | Common Stock |
| Noubar B. Afeyan | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 19,852 | 19,852 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 52,941 | 52,941 | - | - | Stock Option (Right to Buy) |